The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)

Imatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases. Recent screens carried out to find off-target proteins that bind to imatinib identified the oxidoreductase NQO2, a flavoprotein that is phosphorylated in a chronic myelogenous leukemia cell line.


Published in:
BMC structural biology, 9, 7
Year:
2009
Publisher:
BioMed Central
ISSN:
1472-6807
Laboratories:




 Record created 2011-03-21, last modified 2018-09-13

Publisher's version:
Download fulltext
PDF

Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)